Please note that due to ongoing research on this disease, Antagene and CNRS REQUIRE A BLOOD SAMPLE for all HS tests. An exception is made and cheek swabs will be accepted for puppies less than 3 months old.
August 1, 2016
ANTAGENE Genetic risk test for Histiocytic Sarcoma Pre-Test SH Code 150
Expected results using ANTAGENE’s Pre-Test SH
Based on data analysis of BMD research population
The individuals tested have a four times LOWER risk of developing Histiocytic Sarcoma
Neutral—not predictive of higher or lower risk of developing Histiocytic Sarcoma
The individuals tested have a four times HIGHER risk of developing Histiocytic Sarcoma. The risk of the markers associated with the disease being transmitted to offspring is increased.
Validation steps of the Pre-Test SH; Correlation of Index Results and clinical status:
in 2015, two validation steps have been performed on new populations (718 samples): a European BMD population (656 samples) and a North American BMD population (91 samples). These samples had a well defined status: Affected BMDs had definitive pathology diagnoses of HS and Healthy BMDs were older than 10 years of age, with no diagnosis of cancer.
The correlation between the index and the clinical status of the dogs was calculated. No significant difference of this correlation has been observed between these populations and the French research population, the test was validated on a European BMD population and on North American BMDs.
Healthy dogs, of more than 10 years old (total validation n=303)
- Index A: 41.5%
- Index B: 46.5%
- Index C: 12%
Dogs clinically diagnosed as Histiocytic Sarcoma affected (total validation n=415)
- Index A: 14%
- Index B: 43%
- Index C: 43%
As observed in the above percentages, the A and C index categories of the Pre-Test SH are correlated to the disease status, showing that A dogs are more likely to be healthy and C dogs more likely to be affected. This genetic risk test should not in any way be regarded as diagnostic of HS disease. Rather, the Pre-Test SH should be used as a breeding tool that estimates the probability for a given dog to develop HS and of passing HS risk factors on to its offspring.
Based on the results of the validation population:
- the probability that an A index dog is healthy is 68.3%
- the probability that an affected dog is not A index type is 86%
- the probability that a C index dog is affected is 82.8%
- the probability that a healthy dog is not C index type is 87.8%
Frequency of A, B, C indexes observed in European population (2013-2016):
Based on samples received at ANTAGENE to perform the Pre-Test SH, from the European population (n=757), without clinical status, (note they present a sampling bias), the results give information regarding frequencies observed in Europe.
- Dogs that scored A: 23%
- Dogs that scored B: 44%
- Dogs that scored C: 33%
Recommendations on the use of the Pre-Test SH:
OptiGen strongly recommends that breeders consult BMD breed clubs and health organizations, such as the Berner-Garde Foundation, when making use of ANTAGENE's Pre-Test SH. Although it is obvious that breeders will strive to lower the risk of producing dogs that develop HS, it is also of the utmost importance when selecting breeding pairs that sufficient genetic diversity is maintained in the breed. OptiGen, ANTAGENE and CNRS Canine Genetics team insist on the fact that ANTAGENE Pre-Test SH should be just one of many selection criteria.
An index C dog should not be removed from a breeding program based on its Pre-Test SH status alone, rather it should be mated with the individuals showing Index A or B results. Mating programs should be planned to avoid C x C matings - however even these matings are capable of producing Index A offspring (but with a lower frequency than other matings).
How to Place an order via OptiGen for ANTAGENE's Histiocytic Sarcoma Pre-Test SH:
Due to the early stage of understanding and the need for continued research on the genetic bases of HS in the BMD, multiple signed forms are required in placing an order for the ANTAGENE Pre-Test SH:
- One signed copy of the Memorandum of Agreement (Required for the first order placed by an individual):
- ANTAGENE Sampling Certificate (Required for all orders; includes veterinarian's certification and email address)
- OptiGen Order form - either online or printed (Required)
- ANTAGENE HS Health Questionnaire (optional). The questionnaire is available on ANTAGENE's website at http://www.antagene.com/en/contact/histiocytic-sarcoma-questionnaire.
Please note that in order to receive an authenticated result certificate, the animal must be sampled and it's identity certified by a veterinarian, so Veterinarian's involvement is required
In contrast to the other tests that OptiGen currently offers, the veterinarian's role is to:
- Certify sample's identity (by providing clinician's signature and veterinary license number on ANTAGENE Sampling Certificate)
- Provide clinician's email address to allow for direct reporting and communications with ANTAGENE.
Steps to placing an Order for the ANTAGENE Pre-Test SH:
1. Go to the OptiGen Order Test page to place an online order or download a printable form.
2. Download and sign the ANTAGENE Memorandum of Agreement and the ANTAGENE Sampling Certificate.
3. Take the ANTAGENE Sampling Certificate and the OptiGen order form to the veterinarian's clinic.
4. Make sure the veterinarian signs and certifies the ANTAGENE sampling certificate and also provides an email address on that form
5. Include all required forms in the same shipment with the blood samples. Ship samples to:
Cornell Business and Technology Park
767 Warren Road, Suite 300
Ithaca, NY 14850
The Pre-Test SH results will be sent by ANTAGENE by email (in PDF format) within 10 to 15 days from the reception of the DNA sample at ANTAGENE. Hard copy certificates of the Pre-Test SH will not be mailed to the owner.
Free DNA testing to support continued research and an expanded validation study of HS in the North American BMD population:
OptiGen, in collaboration with ANTAGENE and researchers at the Canine Genetics team of CNRS, Rennes, France, will accept blood and/or tissue samples from 50 Affected BMDs with confirmed diagnoses of HS and 50 Healthy BMDs, for research/expanded validation study.
In brief, all AFFECTED dogs that are being submitted for research, must have a definitive HS diagnosis verified by a pathology report; dogs must be less than 10 years old, have a pedigree and have permanent identification (tattoo or chip).
All NORMAL dogs must be more than 10 years old (born before 2006), with no cancer record as confirmed by licensed veterinarian; pedigree record and tattoo or chip ID must also be provided.
Samples that are approved for the research study will be tested using the Pre-Test SH, free of charge, and the test results will be provided to the clients and their veterinarians and will be included in the research process.
Learn more about the ongoing HS research projects by visiting the Berner International Working Group (IWG).